Online Program Home
My Program

Abstract Details

Activity Number: 484 - Clinical Trial Design- 5
Type: Contributed
Date/Time: Wednesday, August 1, 2018 : 8:30 AM to 10:20 AM
Sponsor: Biopharmaceutical Section
Abstract #328809 Presentation
Title: Assessment of Treatment Effect on Overall Survival in the Presence of Treatment Switching: a Bridging Approach Across Various Modeling Methods
Author(s): Yiyun Tang* and Selaru Paulina and Xin Huang
Companies: Pfizer, Inc. and Pfizer Inc. and Pfizer Inc.
Keywords: Clinical Trial; Cost-effectiveness; Crossover; Treatment Switching; Survival Analysis

In oncology drug development for regulatory approval, it is critical to show direct evidence of clinical benefit (eg overall survival [OS]) or improvement in an established surrogate for clinical benefit (eg progression free survival). In some countries, the OS benefit of the new therapy is directly linked to medical reimbursements or payments. However, the presence of treatment switching to post-randomization medication creates difficulties in estimating the true effectiveness and cost-effectiveness of the new therapy.

Various methods exist to account for treatment switching eg marginal structural models with inverse probability of censoring weights,structural nested model, rank preserving structural failure time model,two-stage adjustment model and semi-competing risks model. We consider the intrinsic connection among all these methods through viewing them under the illness-death, multi-state model framework. Under this framework, the clinical data, study design and model assumptions necessary for each of the models can be taken into consideration systematically, thus leading to more robust conclusions and potentially facilitating the drug approval and reimbursement process.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2018 program